Medical/Pharmaceuticals
HoneyNaps Expands into Boston's Kendall Square, Accelerating Global Partnerships in AI Sleep Healthcare
* New office in Boston-Cambridge innovation hub to expand partnerships with healthcare and life sciences leaders * Supported through a Korea Health Industry Development Institute global expansion program * Strategic move expected to accelerate commercialization, clinical collaborations, and...
2026-04-28 19:00
3880
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officia...
2026-04-28 16:07
5380
AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology
QINGDAO, China, April 27, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Company is establishing the foundati...
2026-04-27 21:00
4209
Classys Emerges as a Global Leader in Medical Aesthetics Beyond K-Beauty, Highlighting 45% Growth, 50%+ Margins, and Recurring Revenue Model
– Operations in 80+ countries with over 45,000 installed platforms and 66% international revenue mix – Consumables account for 46% of revenue, with more than 5.5 million HIFU procedures performed annually worldwide – Accelerating growth through two strategic M&A transactions over the past two yea...
2026-04-27 21:00
5629
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
* Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY * Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion * Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI ,April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 60...
2026-04-27 17:03
6205
The World's First Open-Source Medical Video LLM Released, Calling the Global Developer Community to Push It Further
SHANGHAI, April 24, 2026 /PRNewswire/ -- United Imaging Intelligence (UII) has unveiled uAI NEXUS MedVLM, a pioneering Medical Video Large Language Model that delivers unprecedented spatial and temporal precision in clinical environments. UII is fully open-sourcing the model and introducing a new...
2026-04-24 21:19
4469
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...
2026-04-24 21:00
4238
Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...
2026-04-24 20:00
3774
CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'
* Patient-specific titanium implant designed for cranial and craniofacial reconstruction * First Korean company to obtain FDA 510(k) clearance for a customized titanium implant in the U.S. market SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- CGBIO (CEO: Hyunseung Yu) announced that its...
2026-04-24 20:00
4216
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...
2026-04-24 19:30
4364
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...
2026-04-24 19:03
3989
CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair
Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...
2026-04-24 14:58
3701
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...
2026-04-23 15:00
4625
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug P...
2026-04-23 14:14
4185
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in...
2026-04-23 11:37
4313
Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are considered "druggable," and notably, all approved drug...
2026-04-22 21:00
4974
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative dr...
2026-04-22 17:40
4899
Samsung Biologics Reports First Quarter 2026 Financial Results
* Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion * Performance driven by full utilization across Plants 1 through 4 and robust operational execution * Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEO...
2026-04-22 14:50
5457
NEW TELE-DENTISTRY PROGRAMME SUPPORTS EARLY INTERVENTION FOR CHILDREN AT RISK OF CARIES
Targeting vulnerable families, the collaborative programme empowers parents with personalised insights and clear, prioritised guidance for their children's oral care SINGAPORE, April 22, 2026 /PRNewswire/ -- For many families, dental care decisions tend to be reactive, made only when a child exp...
2026-04-22 14:46
4266
ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
* ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology * Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical...
2026-04-22 14:13
3080
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51